CA
ACER

Crewe Advisors’s Acer Therapeutics Inc ACER Stock Holding History

Crewe Advisors’s Portfolio ACER Stock Details ACER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-80
Closed – – 494
2020
Q4 		$0 Hold
80
– – ﹤0.01% 663
2020
Q3 		$0 Hold
80
– – ﹤0.01% 643
2020
Q2 		$0 Hold
80
– – ﹤0.01% 234
2020
Q1 		$0 Hold
80
– – ﹤0.01% 255
2019
Q4 		$0 Hold
80
– – ﹤0.01% 286
2019
Q3 		$0 Buy
+80
New +$235 ﹤0.01% 322

Other funds holding ACER

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Crewe Advisors's ACER Position: Q1 2021 in Review

Crewe Advisors sold out of Acer Therapeutics Inc (ACER) in Q1 2021, closing a stake of 80 shares.

Crewe Advisors first reported a position in ACER in Q3 2019 and held it in 6 quarters. The position peaked at $0 in Q4 2020. 30 funds tracked by Wall St. Rank hold ACER as of Q1 2021.

  • Crewe Advisors reported no remaining Acer Therapeutics Inc position as of Q1 2021 after selling out during the quarter.
  • Crewe Advisors sold 80 Acer Therapeutics Inc shares in Q1 2021.
  • Crewe Advisors first reported a position in Acer Therapeutics Inc in Q3 2019 and held it in 6 quarters.
  • Crewe Advisors's Acer Therapeutics Inc position peaked at $0 in Q4 2020.
  • 30 funds tracked by Wall St. Rank held Acer Therapeutics Inc as of Q1 2021.

Based on Crewe Advisors's 13F filing for Q1 2021, filed 21 Apr 2021.